Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cedars-Sinai Medical Center

Latest From Bial-Portela & CA SA

CHMP’s March Recommendations Include Dinutuximab, Nonacog Beta Pegol And Trumenba

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) meets monthly to review applications for centralized EU marketing authorization. Here’s a summary of their March 2017 recommendations.

Approvals Europe

Deal Watch: Best Value For Smaller Firms Lies In The Back-End

With more deals on earlier-stage platform technologies and compounds, the companies offering such assets need to take a rational approach to pricing – accepting a lot of potential back-end compensation – to get fair value, one analyst says.

Deals M & A

2016 – The Pharma Year In Review

As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.

Brexit Commercial

R&D Matters – The Five Top Research & Development Stories of 2016

If you take the temperature of R&D productivity you get a good indicator of the health of the pharma and biotech industries, making new drug development stories a perennial favourite with Scrip readers. Here we take a look at the five biggest R&D stories this year.

Clinical Trials Research & Development
See All